AEM vs KRO

AEM's deterministic health score is concerning with a Piotroski F-Score of 4/9, indicating marginal financial stability, while the absence of an Altman Z-Score limits distress risk assessment. Despite strong profitability metrics—ROE of 15.67%, gross margin of 70.24%, and robust earnings growth of 85.8% YoY—the stock trades at a premium valuation (P/E 31.23 vs sector avg 25.89) above both the Graham Number ($85.07) and intrinsic value estimate ($202.66). Strong recent price performance (+145% 1Y) and analyst buy recommendation are counterbalanced by weak technical trend (10/100) and limited insider sentiment (40/100). The balance between operational strength and valuation concerns leads to a neutral stance.

KRO exhibits severe financial weakness, anchored by a Piotroski F-Score of 2/9, indicating poor operational health and deteriorating fundamentals. The company transitioned from a profit in 2024 to a net loss of $110.9 million in 2025, driven by the cyclical downturn in the TiO2 market and unabsorbed fixed costs. Despite a low Price-to-Sales ratio and a strong current ratio, the company is plagued by negative profit margins and a consistent track record of missing earnings estimates (0/4 beats in the last year). With the current price of $7.21 trading significantly above the analyst target of $5.50, the risk-reward profile is unfavorable.